EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3

Luke J Laffin, Stephen J Nicholls, Russell S Scott, Peter M Clifton, John Baker, Ashish Sarraju iD, Shweta Singh, Qiuqing Wang, Kathy Wolski, Huansheng Xu, Jen Nielsen, Naimish Patel und 2 weitere

New England Journal of Medicine · 27.11.2025 · 393 (21) · 2119-2130

DOI: 10.1056/nejmoa2511778 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 27.11.2025. Verfasst von Luke J Laffin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 3, CRISPR-Cas Systems, Dyslipidemias, Gene Editing. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: CRISPR Therapeutics AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiopoietin-Like Protein 3CRISPR-Cas SystemsDyslipidemiasGene EditingRNA, Guide, CRISPR-Cas SystemsAdultAgedFemaleHumansMaleMiddle AgedHypercholesterolemiaHypertriglyceridemiaLoss of Function MutationInfusions, IntravenousTreatment Outcome

Substanzen

Angiopoietin-Like Protein 3ANGPTL3 protein, humanRNA, Guide, CRISPR-Cas Systems

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland.
  • Cleveland Clinic Coordinating Center for Clinical Research, Cleveland.
  • Victorian Heart Institute, Monash University, Melbourne, VIC, Australia.
  • New Zealand Clinical Research, Christchurch, New Zealand.
  • Royal Adelaide Hospital, Adelaide, SA, Australia.
  • Aotearoa Clinical Trials, Auckland, New Zealand.

ORCID-Profile: Ashish Sarraju, Steven E Nissen

Förderung

  • CRISPR Therapeutics AG

Zitieren

APA

Laffin, L. J., Nicholls, S. J., Scott, R. S., Clifton, P. M., Baker, J., Sarraju, A., Singh, S., Wang, Q., Wolski, K., Xu, H., Nielsen, J., Patel, N., Duran, J. M., & Nissen, S. E. (2025). Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. New England Journal of Medicine, 393(21), 2119-2130. https://doi.org/10.1056/nejmoa2511778

Vancouver

Laffin LJ, Nicholls SJ, Scott RS, Clifton PM, Baker J, Sarraju A, et al. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. New England Journal of Medicine. 2025;393(21):2119-2130. doi:10.1056/nejmoa2511778

BibTeX
@article{Laffin2025,
  author = {Laffin, Luke J and Nicholls, Stephen J and Scott, Russell S and Clifton, Peter M and Baker, John and Sarraju, Ashish and Singh, Shweta and Wang, Qiuqing and Wolski, Kathy and Xu, Huansheng and Nielsen, Jen and Patel, Naimish and Duran, Jason M and Nissen, Steven E},
  title = {Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {21},
  pages = {2119--2130},
  doi = {10.1056/nejmoa2511778}
}
Kostenlos starten →